PMCTPharmaCountry
    Home

Analysis

In-depth analysis of pharmaceutical markets, supply chains, technology and regulation

#HK Innoen ×

Analysis
Sep 1, 2026•1 min read
HK Innoen's K‑Cap (Tegoprazan) Targets US Launch, Boosts Growth Prospects
Domestic drug K‑Cap (tegoprazan) is nearing US market entry, with analysts seeing royalty revenue and a shift to global growth for HK Innoen.